Data Presented at the 2020 American College of Allergy, Asthma and Immunology Virtual Annual Scientific Meeting OSAKA, Japan — (BUSINESS WIRE) — Takeda Pharmaceutical Company Limit…
Final Results from the Phase 3 HELP Study™ Open-Label Extension Support TAKHZYRO® (lanadelumab-flyo) Injection as a Long-term Preventive Treatment Option in Patients with Hereditary Angioedema
Data Presented at the 2020 American College of Allergy, Asthma and Immunology Virtual Annual Scientific Meeting OSAKA, Japan — (BUSINESS WIRE) — Takeda Pharmaceutical Company Limit…